NTRA Stock Overview
A diagnostics company, develops and commercializes molecular testing services worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Natera, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$97.75 |
52 Week High | US$117.23 |
52 Week Low | US$36.90 |
Beta | 1.48 |
11 Month Change | -9.73% |
3 Month Change | 3.82% |
1 Year Change | 115.50% |
33 Year Change | -11.81% |
5 Year Change | 265.56% |
Change since IPO | 329.86% |
Recent News & Updates
Recent updates
Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?
Jul 05Natera: Overdue For A Breather
Jun 03Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119
May 12Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?
Mar 30Natera: Capitalizing On The Positive Momentum Of Personalized Medicine
Mar 22Is Natera (NASDAQ:NTRA) A Risky Investment?
Mar 03Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)
Dec 11Is Natera (NASDAQ:NTRA) A Risky Investment?
Nov 10Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate
Aug 07Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?
May 16Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement
Apr 18Natera: Cracks In The Bearish Trade
Oct 10Shareholder Returns
NTRA | US Biotechs | US Market | |
---|---|---|---|
7D | -8.2% | 2.2% | -2.3% |
1Y | 115.5% | 16.5% | 16.9% |
Return vs Industry: NTRA exceeded the US Biotechs industry which returned 15.3% over the past year.
Return vs Market: NTRA exceeded the US Market which returned 16.9% over the past year.
Price Volatility
NTRA volatility | |
---|---|
NTRA Average Weekly Movement | 5.7% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTRA has not had significant price volatility in the past 3 months.
Volatility Over Time: NTRA's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 3,288 | Steve Chapman | www.natera.com |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.
Natera, Inc. Fundamentals Summary
NTRA fundamental statistics | |
---|---|
Market cap | US$12.74b |
Earnings (TTM) | -US$365.46m |
Revenue (TTM) | US$1.21b |
9.9x
P/S Ratio-32.8x
P/E RatioIs NTRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NTRA income statement (TTM) | |
---|---|
Revenue | US$1.21b |
Cost of Revenue | US$600.85m |
Gross Profit | US$607.71m |
Other Expenses | US$973.17m |
Earnings | -US$365.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | -2.98 |
Gross Margin | 50.28% |
Net Profit Margin | -30.24% |
Debt/Equity Ratio | 45.8% |
How did NTRA perform over the long term?
See historical performance and comparison